News

The investigators assessed the proportion of households that chose to eliminate allergens by specific allergies to foods and to evaluate related psychosocial functioning among families.

A study found that NT-proBNP levels predict cardiovascular and renal risks in patients with advanced CKD and anemia. Greater NT-proBNP variability showed increased renal risks.

In this episode, hosts discuss a slight dip in US obesity rates, the use of inhaled insulin, and the benefit of mifepristone for HbA1c reduction.

In this analysis, baseline peanut sIgE was shown to be a stronger predictor of remission after peanut OIT than age at the beginning of immunotherapy treatment.

The December month in review spotlights hepatic FDA news as well as the latest research in viral hepatitis and MASH.

Bendapudi gave an overview of 2 studies presented at ASH 2024 from his Harvard lab.

Potassium nitrate increased blood nitric oxide metabolites but showed no improvement in exercise tolerance or quality of life in a population with HFpEF.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

These data highlight long-term complications related to COVID-19 in terms of skin conditions, a continuing concern for many patients.

Rani discussed an in-depth study examining quality of sleep and quality of life in children and adolescents with SCD.

A list recapping our most popular endocrinology coverage from the past year.

Patients hospitalized for severe COVID-19 had an accelerated eGFR decline relative to those with pneumonia due to other infections.

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

Lungcast reflects on this year in pulmonology, looking back at such topics ranging from the American Lung Association ‘State of the Air’ report to artificial intelligence in lung imaging.

The field of allergy medicine this year saw a variety of developments, including the FDA approvals of neffy and omalizumab as well as new data on immunotherapy.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

The field of dermatology saw a wide array of notable developments this year, with highlights including FDA approvals as well as notable clinical trial results.

Neurokinin-3 receptor antagonists such as elinzanetant and fezolinetant provide non-hormonal options for managing hot flashes linked to menopause.

2024 was a historic year in hepatology, characterized by notable hepatic FDA approvals, pipeline developments, new WHO HBV guidelines, and more.

A look back at some of our top coverage in ophthalmology from 2024, including pipeline news and FDA approvals.

Resmetirom made history when it became the first and only FDA-approved MASH drug in 2024, but the pipeline continues to show promise heading into 2025.

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.

The proposed rule seeks to establish and require standardized testing methods to detect and identify asbestos in cosmetic products with talc.

We spotlight 5 impactful regulatory decisions scheduled to occur during the first quarter of 2025.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

From FDA approvals to updated guidelines, 2024 brought transformative advancements in sleep medicine, offering new hope for managing complex sleep disorders.

In this episode of Crisis Point, this year’s news regarding benzene found in acne products is discussed by David Light, Neal Bhatia, MD, and Christopher Bunick, MD, PhD.